Vectus Biosystems Company
From 20 years of scientific observations of metabolic change as a result of salt intake, came the discovery by Dr Karen Duggan in 2003 that a naturally occurring molecule in the human body was capable of reversing fibrosis caused by hypertension and other chronic diseases such as diabetes. In 2005 Vectus Biosystems Limited was formed to take Dr Duggan’s discovery through to an orally deliverable drug.
Technology:
Immunotherapy
Industry:
Geroscience
Headquarters:
Sydney, New South Wales, Australia
Zip:
1-10
Founded Date:
2005-01-01
Employees Number:
1-10
Funding Status:
IPO
Total Funding:
Less than $1M
Estimated Revenue:
2016-02-26
Last Funding Date:
2016-02-26
Last Funding Type:
info@vectusbiosystems.com.au
Register and Claim Ownership